Gorman EA, O’Kane CM, McAuley DF. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management. Lancet. 2022;400(10358):1157–70.
Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA. 2018;319(7):698–710.
Ma W, Tang S, Yao P, Zhou T, Niu Q, Liu P, et al. Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies. Signal Transduct Target Ther. 2025;10(1): 75.
Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet. 2022;400(10358):1145–56.
Sun ZC, Liao R, Xian C, Lin R, Wang L, Fang Y, et al. Natural pachypodol integrated, lung targeted and inhaled lipid nanomedicine ameliorates acute lung injury via anti-inflammation and repairing lung barrier. J Control Release. 2024;375:300–15.
Xu Y, Lv L, Wang Q, Yao Q, Kou L, Zhang H. Emerging application of nanomedicine-based therapy in acute respiratory distress syndrome. Colloids Surf B Biointerfaces. 2024;237: 113869.
Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18.
Chen T, Zhu G, Meng X, Zhang X. Recent developments of small molecules with anti-inflammatory activities for the treatment of acute lung injury. Eur J Med Chem. 2020;207: 112660.
Roquilly A, Jacqueline C, Davieau M, Mollé A, Sadek A, Fourgeux C, et al. Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis. Nat Immunol. 2020;21(6):636–48.
Chen X, Tang J, Shuai W, Meng J, Feng J, Han Z. Macrophage polarization and its role in the pathogenesis of acute lung injury/acute respiratory distress syndrome. Inflamm Res. 2020;69(9):883–95.
Liang L, Peng W, Qin A, Zhang J, Chen R, Zhou D, et al. Intracellularly synthesized artificial exosome treats acute lung injury. ACS Nano. 2024;18(32):21009–23.
Park MD, Silvin A, Ginhoux F, Merad M. Macrophages in health and disease. Cell. 2022;185(23):4259–79.
Liang L, Xu W, Shen A, Fu X, Cen H, Wang S et al. Inhibition of YAP1 activity ameliorates acute lung injury through promotion of M2 macrophage polarization. MedComm (2020). 2023, 4(3):e293.
Li X, Chen G, Zhou X, Peng X, Li M, Chen D, et al. Roles of Akirin1 in early prediction and treatment of graft kidney ischemia–reperfusion injury. Smart Medicine. 2024;3(2): e20230043.
Li J, Jiang X, Li H, Gelinsky M, Gu Z. Tailoring materials for modulation of macrophage fate. Adv Mater. 2021;33(12): e2004172.
Chen S, Saeed A, Liu Q, Jiang Q, Xu H, Xiao GG, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1): 207.
Liu C, Xi L, Liu Y, Mak JCW, Mao S, Wang Z, et al. An inhalable hybrid biomimetic nanoplatform for sequential drug release and remodeling lung immune homeostasis in acute lung injury treatment. ACS Nano. 2023;17(12):11626–44.
Zhu Q, Yu T, Gan S, Wang Y, Pei Y, Zhao Q, et al. TRIM24 facilitates antiviral immunity through mediating K63-linked TRAF3 ubiquitination. J Exp Med. 2020;217(7): e20192083.
Yu T, Gan S, Zhu Q, Dai D, Li N, Wang H, et al. Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. Nat Commun. 2019;10(1):4353.
Guan X, Xu X, Tao Y, Deng X, He L, Lin Z, et al. Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy. J Nanobiotechnol. 2024;22(1):692.
Huang JH, Huang CJ, Yu LN, Guan XL, Liang SW, Li JH, et al. Bioinspired PROTAC-induced macrophage fate determination alleviates atherosclerosis. Acta Pharmacol Sin. 2023;44(10):1962–76.
Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020, 367(6478):eaau6977. https://doi.org/10.1126/science.aau6977
Zhu L, Tian W, Yuan L, Chi C, Wang Y, Xiao Q, et al. Aptamer-based extracellular vesicle isolation, analysis and therapeutics. Interdiscip Med. 2023;1(2): e20220019.
Qiao R, Wang H, Li D, Yang Y, Shu J, Song X, et al. Stevioside protects against acute kidney injury by inhibiting gasdermin D pathway. Smart Medicine. 2024;3(2): e20240010.
Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, et al. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer. 2022;21(1):56.
Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183–95.
Wang J, Yuan S, Tu Y, Lv Z, Cheng H, Ding X. Extracellular vesicles in skin health, diseases, and aging. Interdiscip Med. 2024;2: e20240011.
Chavda VP, Pandya A, Kumar L, Raval N, Vora LK, Pulakkat S, et al. Exosome nanovesicles: a potential carrier for therapeutic delivery. Nano Today. 2023;49:101771.
Gui X, Zhang H, Zhang R, Li Q, Zhu W, Nie Z, et al. Exosomes incorporated with black phosphorus quantum dots attenuate retinal angiogenesis via disrupting glucose metabolism. Mater Today Bio. 2023;19: 100602.
Wang P, Wang H, Huang Q, Peng C, Yao L, Chen H, et al. Exosomes from M1-polarized macrophages enhance Paclitaxel antitumor activity by activating macrophages-mediated inflammation. Theranostics. 2019;9(6):1714–27.
Gunassekaran GR, Poongkavithai Vadevoo SM, Baek MC, Lee B. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021;278:121137.
Du T, Yang CL, Ge MR, Liu Y, Zhang P, Li H, et al. M1 macrophage derived exosomes aggravate experimental autoimmune neuritis via modulating Th1 response. Front Immunol. 2020;11:1603.
Liu C, Zhang W, Li Y, Chang J, Tian F, Zhao F, et al. Microfluidic sonication to assemble exosome membrane-coated nanoparticles for immune evasion-mediated targeting. Nano Lett. 2019;19(11):7836–44.
Zhang H, Mao Y, Nie Z, Li Q, Wang M, Cai C, et al. Iron oxide nanoparticles engineered macrophage-derived exosomes for targeted pathological angiogenesis therapy. ACS Nano. 2024;18:7644–55.
Lin Y, Guan X, Su J, Chen S, Fu X, Xu X, et al. Cell membrane-camouflaged nanoparticles mediated nucleic acids delivery. Int J Nanomedicine. 2023;18:8001–21.
Li H, Li S, Lin Y, Chen S, Yang L, Huang X, et al. Artificial exosomes mediated spatiotemporal-resolved and targeted delivery of epigenetic inhibitors. J Nanobiotechnol. 2021;19(1):364.
Lan Q, Liu C, Yang F, Liu S, Xu J, Sun D. Synthesis of bilayer oleic acid-coated Fe3O4 nanoparticles and their application in pH-responsive Pickering emulsions. J Colloid Interface Sci. 2007;310(1):260–9.
Zhang D, Teng KX, Zhao L, Niu LY, Yang QZ. Ultra-small nano-assemblies as tumor-targeted and renal clearable theranostic agent for photodynamic therapy. Adv Mater. 2023;35(19): e2209789.
Zoulikha M, Xiao Q, Boafo GF, Sallam MA, Chen Z, He W. Pulmonary delivery of SiRNA against acute lung injury/acute respiratory distress syndrome. Acta Pharm Sin B. 2022;12(2):600–20.
Martin TR, Zemans RL, Ware LB, Schmidt EP, Riches DWH, Bastarache L, et al. New insights into clinical and mechanistic heterogeneity of the acute respiratory distress syndrome: summary of the Aspen Lung Conference 2021. Am J Respir Cell Mol Biol. 2022;67(3):284–308.
Qiao Q, Liu X, Yang T, Cui K, Kong L, Yang C, et al. Nanomedicine for acute respiratory distress syndrome: the latest application, targeting strategy, and rational design. Acta Pharm Sin B. 2021;11(10):3060–91.
Liao R, Sun ZC, Wang L, Xian C, Lin R, Zhuo G, et al. Inhalable and bioactive lipid-nanomedicine based on Bergapten for targeted acute lung injury therapy via orchestrating macrophage polarization. Bioact Mater. 2025;43:406–22.
Békés M, Langley DR, Crews CM. Protac targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181–200.
Huang J, Yao Z, Li B, Ping Y. Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy. J Control Release. 2023;361:270–9.
Yang L, Yang Y, Zhang J, Li M, Yang L, Wang X, et al. Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy. Signal Transduct Target Ther. 2024;9(1): 275.
Zhang HT, Peng R, Chen S, Shen A, Zhao L, Tang W, et al. Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy. Adv Sci. 2022;9(29):e2202039.
Zhang Y, Liu Q, Zhang X, Huang H, Tang S, Chai Y, et al. Recent advances in exosome-mediated nucleic acid delivery for cancer therapy. J Nanobiotechnol. 2022;20(1):279.
Duan L, Xu L, Xu X, Qin Z, Zhou X, Xiao Y, et al. Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale. 2021;13(3):1387–97.
Zhang L, Lin Y, Li S, Guan X, Jiang X. In situ reprogramming of tumor-associated macrophages with internally and externally engineered exosomes. Angew Chem Int Ed. 2023;62(11): e202217089.
Lin Y, Yi M, Guan X, Chen E, Yang L, Li S, et al. Two birds with one stone strategy for the lung cancer therapy with bioinspired AIE aggregates. J Nanobiotechnol. 2023;21(1):49.
Tian Y, Han W, Yeung KL. Magnetic microsphere scaffold-based soft microbots for targeted mesenchymal stem cell delivery. Small. 2023;19(32): e2300430.
Li N, Fei P, Tous C, Rezaei Adariani M, Hautot ML, Ouedraogo I, et al. Human-scale navigation of magnetic microrobots in hepatic arteries. Sci Robot. 2024;9(87): eadh8702.
Chen J, Ren T, Xie L, Hu H, Li X, Maitusong M, et al. Enhancing aortic valve drug delivery with PAR2-targeting magnetic nano-cargoes for calcification alleviation. Nat Commun. 2024;15(1):557.
Zhang H, Li Z, Gao C, Fan X, Pang Y, Li T, et al. Dual-responsive biohybrid neutrobots for active target delivery. Sci Robot. 2021;6(52): eaaz9519.
Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9–17.
Nowak-Jary J, Machnicka B. Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications. J Nanobiotechnol. 2022;20(1):305.
Zhao D, Zhu T, Li J, Cui L, Zhang Z, Zhuang X, Ding J. Poly(lactic-co-glycolic acid)-based composite bone-substitute materials. Bioact Mater. 2021;6(2):346–60.
